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ABSTRACT
Background: Non-invasive ventilation (NIV) is a valuable treatment in the management of acute hypercapnic respiratory 
failure. NIV is not without risks. One such adverse effect is the development of pressure ulcers over the nasal bridge which have 
an incidence of up to 20% of patients requiring NIV in this setting. The role of medical devices in the development of hospital 
acquired pressure ulcers has been increasingly recognised with 10-35% of all hospital acquired ulcers attributed to medical 
devices.  Guidelines on acute NIV use suggest good skin care strategies. However, data on the magnitude of the problem of 
nasal bridge pressure ulceration and the effect of proactive preventative steps remains scant.
Method: A quality improvement project was designed to reduce the incidence of nasal bridge pressure ulcers during acute NIV. 
Hydrocolloid dressings were placed over the nasal bridge in all patients requiring NIV between 30th October 2015 and the 29th 
October 2016.  Tissue viability was assessed daily with new pressure ulceration defined as grade 2 or above. Rates of nasal 
bridge pressure ulcers were compared to all patients requiring NIV in the 12-month period prior to intervention.
Results: In Group 1, there were 161 admissions and 9 grade 2 pressure ulcers from 666 NIV bed-days. In Group 2 there were 
134 admissions and 0 pressure ulcers from 718 NIV bed-days. There was a statistically significant reduction in grade 2 pressure 
ulceration rates (p= 0.0013) in Group 2 compared to Group 1.
Conclusion: Application of an early prophylactic pressure-relieving hydrocolloid nasal dressing reduces the risk of developing 
grade 2 pressure ulcers in patients in patients requiring acute NIV.
INTRODUCTION
Non-invasive ventilation (NIV) is a valuable treatment for 
acute hypercapnic respiratory failure.  Use of ward based 
NIV is increasing, with approximately 9000 episodes yearly 
within the UK1.   Exacerbations of COPD remain the most 
common indication2 with hypercapnic respiratory failure 
complicating up to 20% of acute admissions3.  NIV has been 
shown to reduce mortality4 and avoids the need for intubation 
thereby avoiding associated complications such as ventilator 
associated pneumonia.  The use of NIV is not without risks. 
These range from relatively minor complications to more 
clinically significant effects, such as a heightened risk of 
aspiration, and untoward haemodynamic effects.6 The impact 
of the device itself on the skin and the predisposition to skin 
breakdown in this context is now appreciated to be another 
clinically significant untoward effect of NIV.6 
The role of medical devices in the development of hospital 
acquired pressure ulcers has been increasingly recognised 
over recent years.  A variety of medical devices have been 
shown to increase the risk with patients 2.4 times more likely 
to develop a pressure ulcer if any medical device is used7.  10-
35% of hospital acquired pressure ulcers are directly related 
to medical devices7,8.    
Nasal bridge pressure ulcers related to the use of NIV masks 
occur in 5-20% cases5,6,9.  The development of pressure lesions 
can result in intolerance to NIV and potentially treatment 
failure. Patient comfort and enhanced compliance are key 
factors in determining NIV outcome.  Lesions develop as a 
result of pressure exerted by the mask which can approach 
pressures of 70mmHg10.  In the presence of shear forces, such 
as that generated between inspiratory and expiratory phases of 
ventilation, pressures of as low as 30mmHg may be sufficient 
to result in tissue damage within a few hours11.
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Current guidelines regarding the management of NIV suggest 
ensuring best mask fit along with pressure relieving strategies. 
This includes regular breaks from the mask, alternating 
between two interface types or barrier dressings9, however 
data regarding this is lacking. Our objective was to examine 
the effect of a proactive approach to reducing grade 2 or 
above nasal bridge pressure ulcers in patients requiring acute 
NIV.  We aimed to reduce the incidence of pressure ulcers by 
using a hydrocolloid dressing placed over the nasal bridge 
throughout the episode of NIV. 
METHODS
Aim: We designed a quality improvement project to assess 
the effect of a proactive preventative approach towards nasal 
bridge pressure ulceration through the prophylactic use of 
a hydrocolloid dressing on the incidence of nasal bridge 
pressure ulcers in patients requiring acute non-invasive 
ventilation. This study is a report of a Quality Improvement 
Project (QIP) performed as a systematic, data-guided activity 
designed to bring about immediate improvements in health 
delivery.  This QIP was registered on the audit database 
managed by the Clinical Standards Committee of the Heart 
of England NHS Foundation Trust, Birmingham, B9 5SS, 
UK.  Data was collected from the continuous audit of all NIV 
admissions registered with the audit database of the Heart of 
England NHS Foundation Trust (audit registration number: 
2399). Rates of development of nasal bridge pressure ulcers 
were compared to all patients requiring NIV in the 12-month 
period prior to intervention.
Subjects and intervention: We aimed to do a pre and post 
observational study following the introduction of the proactive 
preventative approach. Consecutive patients admitted to our 
dedicated physiotherapy-led, respiratory ward based NIV 
unit requiring NIV for acute hypercapnic respiratory failure 
between 30th October 2014 to -30th October 2015 were 
included.  NIV was delivered in a ward-based setting using 
standard non-invasive ventilators in spontaneous-timed (ST) 
and volume-assured Pressure support modes via a FreeMotion 
RT040 (Fisher Paykel) oronasal mask sized according to 
manufacturer instructions.  NIV settings were managed 
according to local protocols based on British Thoracic Society 
guidelines for the use of acute NIV.  
Group 1 included all patients commencing NIV between 30th 
October 2014 and 29th October 2015, who received usual 
care.  Group 2 included all patients commencing NIV between 
30th October 2015 and 29th October 2016.  Group 2 received 
hydrocolloid dressings (BeneHold Bordered Hydrocolloid 
dressing 5cm x 5cm [Aspen Medical]) which were positioned 
in a diamond formation over the centre of the forehead with 
Fig 2. Application of hydrocolloid dressings to prevent nasal 
bridge ulceration (black arrows)
Fig 1. Top – A typical full face mask used for acute non-invasive 
ventilation: the nasal bridge is the most prominent bony structure 
in contact with the mask cushion (white arrow); Bottom – Grade 2 
Nasal bridge pressure ulcer (bordered arrow)
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a further dressing positioned as a diamond over the nasal 
bridge.  The NIV mask was placed over this.  All other care, 
including NIV pressure changes and breaks off NIV, was 
given according to local protocols which remained unchanged 
between the time periods.
Data collection: Data regarding age, sex, admission 
diagnosis, co-morbidity, length of NIV use, IPAP, EPAP, and 
nasal bridge tissue viability grading was recorded.  The nasal 
bridge was formally inspected daily by a nurse trained in skin 
and pressure ulcer grading.  Inspection involved removing 
the hydrocolloid dressing and assessment using hospital 
guidelines adapted from NPUAP/EPUAP pressure ulcer 
classification system.  A pressure ulcer was diagnosed when 
criteria for grade 2 pressure change (partial thickness skin loss 
involving epidermis, dermis or both) was observed.  If there 
was no evidence of pressure change or grade 1 change only, 
a new hydrocolloid dressing was placed and NIV continued 
via oronasal mask.  
Statistical analysis: Chi squared and Fisher exact tests were 
used for analysis of incidence of grade 2 pressure ulcers 
between groups and other categorical data.  Mann Whitney 
U test was used to analyse all other variables.
RESULTS
A total of 295 patients were included, 161 in Group 1 (pre) and 
134 in Group 2 (post).  1 patient in Group 1 had incomplete 
records regarding co-morbidities and was excluded from 
analysis of this parameter, but all other categories were 
complete and the patient was therefore included in the study. 
Demographics including sex and age, and diagnosis or 
reason for commencement of NIV did not differ significantly 
between groups (Table 1).  
Pressure ulcer incidence: Pressure ulcer development 
differed significantly (p=0.001) between groups.  For Group 
1, 9 out of 161 episodes of acute NIV resulted in a grade 2 
nasal bridge pressure ulcer during 666 NIV bed days.  As for 
Group 2, none of 134 episodes of acute NIV resulted in a 
grade 2 nasal bridge pressure ulcer during 718 NIV bed days. 
IPAP and EPAP used were not significantly difference 
between groups (IPAP p=0.110, Group 1 mean 19.8 [median 
20, IQR 16-24], Group 2 mean 19.0 [median 18, IQR 16-22], 
EPAP p=0.100, Group 1 mean 6.1 [median 6, IQR 5-7], Group 
2 mean 5.68 [median 6, IQR 5-6]).
Co-morbidity: Co-morbidities considered to have an 
association with an increased risk of pressure ulcers were not 
significantly difference between groups (Table 2).
Adverse effects: There were no local adverse effects (eg rash, 
contact dermatitis) related to dressings.
DISCUSSION
The use of prophylactic hydrocolloid dressings placed over 
the bridge of the nose effectively removed the risk of grade 
2 nasal bridge pressure ulcers.  Previous studies have shown 
the incidence of nasal bridge pressure ulcers during the use 
of acute NIV to be between 5-20%5,6,9.  The incidence in our 
pre-intervention group was 6%.  There were no ulcers evident 
in the intervention group.
The development of pressure ulcers related to NIV is due to 
a combination of pressure effects and shear forces exerted by 
the presence of the mask, pressure changes during different 
phases of ventilation, and mask strap tension6,10,11.  The use 
of oronasal masks and increasing time spent on NIV increase 
the risk of pressure ulcers forming, as do patient factors 
including age, sensory impairment, chronic skin conditions, 
and hypotension amongst others.5 
Previous studies into reducing NIV related pressure ulcers 
have examined the effect of dispersing pressure effects by 
changing the interface from an oronasal mask to a full face 
or helmet mask with a significant reduction in the incidence 
of pressure ulcers13.  With regard to ventilation there is no 
evidence that any one interface is superior.  Laboratory 
modelling suggested an increase in the internal volume of 
the interface may increase dead space and CO2 rebreathing14, 
Table 1: 
Patient demographics and primary clinical indication for NIV
Group 1 (161 episodes NIV) Group 2 (134 episodes NIV) P value
Male 70 (43.5%) 46 (34.3%) 0.109
Age (mean years) 69.7 69.2 0.610
Diagnosis
COPD
Obesity
Musculoskeletal
Other
129 (80.1%)
11 (6.8%)
6 (3.7%)
15 (9.3%)
110 (82.1%)
13 (9.7%)
3 (2.2%)
8 (6.0%)
0.668
0.369
0.459
0.286
Table 2: 
Comorbidity in patient groups
Co-morbidity Pre Post P value
Diabetes 52 36 0.293
Vascular disease 61 47 0.589
Chronic kidney disease 30 19 0.295
Chronic dermatological 2 0 0.502
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however this has not been borne out in vivo15.  Despite this, 
oronasal masks remain the most popular interface with a 
Europe wide survey showing them to be first choice in 70% of 
cases.  Reasons given by respondents for their choice include 
reduced air leaks, patient comfort and cost13.
Three previous studies examining the effect of dressings in 
reducing nasal bridge pressure ulcers were identified.  Weng 
et al report a significant reduction in grade 1 nasal bridge 
pressure ulcers with both Tegasorb and Tegaderm dressings 
when compared to no intervention17.  Callaghan et al support 
this finding, using Granuflex compared to usual care18. 
Evaluation of a protective solution by Pena-Otero et al found 
a trend towards a protective benefit with use of a solution of 
hyperoxygenated fatty acids but no improvement with either 
an adhesive thin polyurethane dressing or an adhesive foam 
dressing19.  All of these studies were limited by small sample 
sizes with the largest containing only 40 patients per group. 
There is a larger body of evidence that considers more 
traditionally recognised pressure ulcers or ‘bedsores’ rather 
than ulcers related to medical devices.  Preventative measures 
including turning regimes, pressure redistributing devices e.g. 
appropriate mattresses, and optimisation of nutritional status 
are now well known.  Pooled analysis of RCTs of preventative 
dressings within this field demonstrate an overall 79% risk 
reduction in the incidence of new pressure ulcers with use of 
dressings20, although it was noted that the studies included in 
this analysis had a high risk of bias. 
Our study is the assessment of a real-life quality improvement 
project.  It is therefore limited in that its style it is a quasi-
experimental ‘before-and-after’ study, lacking randomisation 
or blinding.  There are a number of potentially confounding 
factors regarding the risk of developing pressure ulcers that 
were not systematically assessed, namely nutritional status 
and use of certain medications such as steroids.  It does, 
however, provide real world data and is therefore easily 
transferrable to practice.  
CONCLUSION
The current evidence base regarding both the incidence of 
nasal bridge pressure ulcers and the effect of preventative 
strategies is limited.  We have demonstrated a strategy to 
reduce the incidence of grade 2 pressure ulcers associated 
with NIV, thereby reducing avoidable harm to patients 
and improving quality and safety of their care.  We would 
therefore advocate the use of hydrocolloid dressings to 
prevent NIV related nasal bridge pressure ulcers.
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